At a glance → Malaria kills over 600,000 people annually, the majority children under five. → DDD107498 discovery won MMV’s Project of the Year 2014 → A phase 1b human clinical study of single oral doses of M5717 demonstrated single dose cure and was recently published in The Lancet
→ Merck KGaA licensed DDD107498, renamed M5717, as their flagship anti-malarial for pre-clinical and clinical development. DDU compound DDD107498 can cure malaria with a single dose costing less than
$1
